{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T14:02:14Z","timestamp":1785506534857,"version":"3.56.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T00:00:00Z","timestamp":1697587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T00:00:00Z","timestamp":1697587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004337","name":"F. Hoffmann-La Roche Ltd","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s40487-023-00245-4","type":"journal-article","created":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T08:02:39Z","timestamp":1697616159000},"page":"495-511","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Multiple Real-World Data Sources in a Bayesian Framework to Inform Long-Term Survival Estimates of Mosunetuzumab in Patients with Follicular Lymphoma"],"prefix":"10.1007","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct02500407","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Javier","family":"Sanchez Alvarez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Jaber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-H\u00e9l\u00e8ne","family":"Blanchet Zumofen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,18]]},"reference":[{"issue":"3","key":"245_CR1","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/ejh.13271","volume":"103","author":"R Dada","year":"2019","unstructured":"Dada R. Diagnosis and management of follicular lymphoma: a comprehensive review. Eur J Haematol. 2019;103(3):152\u201363.","journal-title":"Eur J Haematol"},{"issue":"3","key":"245_CR2","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/ajh.25696","volume":"95","author":"A Freedman","year":"2020","unstructured":"Freedman A, Jacobsen E. Follicular lymphoma: 2020 update on diagnosis and management. Am J Hematol. 2020;95(3):316\u201327.","journal-title":"Am J Hematol"},{"issue":"7","key":"245_CR3","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41408-020-00340-z","volume":"10","author":"CL Batlevi","year":"2020","unstructured":"Batlevi CL, Sha F, Alperovich A, et al. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. Blood Cancer J. 2020;10(7):74.","journal-title":"Blood Cancer J"},{"key":"245_CR4","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41572-019-0132-x","volume":"5","author":"A Carbone","year":"2019","unstructured":"Carbone A, Roulland S, Gloghini A, et al. Follicular lymphoma. Nat Rev Dis Primers. 2019;5:83.","journal-title":"Nat Rev Dis Primers"},{"key":"245_CR5","doi-asserted-by":"publisher","first-page":"18","DOI":"10.21037\/aol-21-5","volume":"5","author":"M Perrett","year":"2021","unstructured":"Perrett M, Okosun J. Genetic heterogeneity in follicular lymphoma. Ann Lymphoma. 2021;5:18.","journal-title":"Ann Lymphoma"},{"issue":"2","key":"245_CR6","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1200\/JCO.18.00400","volume":"37","author":"C Sarkozy","year":"2019","unstructured":"Sarkozy C, Maurer MJ, Link BK, et al. Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US cohorts. J Clin Oncol. 2019;37(2):144\u201352.","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"245_CR7","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1182\/blood-2020-135839","volume":"136","author":"SE Assouline","year":"2020","unstructured":"Assouline SE, Kim WS, Sehn LH, et al. Mosunetuzumab shows promising efficacy in patients with multiply relapsed follicular lymphoma: updated clinical experience from a phase I dose-escalation trial. Blood. 2020;136(suppl 1):42\u20134.","journal-title":"Blood"},{"issue":"suppl 1","key":"245_CR8","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1182\/blood-2021-145872","volume":"138","author":"LE Budde","year":"2021","unstructured":"Budde LE, Sehn LH, Matasar MJ, et al. Mosunetuzumab monotherapy is an effective and well-tolerated treatment option for patients with relapsed\/refractory (R\/R) follicular lymphoma (FL) who have received \u22652 prior lines of therapy: pivotal results from a phase I\/II study. Blood. 2021;138(suppl 1):127.","journal-title":"Blood"},{"issue":"5","key":"245_CR9","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1200\/JCO.21.00931","volume":"40","author":"LE Budde","year":"2022","unstructured":"Budde LE, Assouline S, Sehn LH, et al. Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study. J Clin Oncol. 2022;40(5):481\u201391.","journal-title":"J Clin Oncol"},{"key":"245_CR10","unstructured":"Lunsumio\u00ae (mosunetuzumab-axgb). Prescribing information. Genentech, Inc; 2022."},{"key":"245_CR11","unstructured":"European Medicines Agency. Lunsumio [Summary of Product Characteristics]. Roche Pharma AG; 2022."},{"key":"245_CR12","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s40265-022-01749-5","volume":"82","author":"C Kang","year":"2022","unstructured":"Kang C. Mosunetuzumab: first approval. Drugs. 2022;82:1229\u201334.","journal-title":"Drugs"},{"key":"245_CR13","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for B-Cell Lymphomas Version 5.2023. \u00a9 National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed July 7, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."},{"key":"245_CR14","unstructured":"Spanish Group of Lymphomas\/Autologous Bone Marrow Transplantation (GELTAMO). Clinical guidelines for the Diagnosis and Treatment of Follicular Lymphoma. https:\/\/www.geltamo.com\/actividades-cientificas\/guias-terapeiuticas\/159-guia-clinica-para-el-diagnostico-y-tratamiento-del-linfoma-de-celulas-del-manto. Accessed July 2023."},{"key":"245_CR15","unstructured":"German Society for Haematology and Medical Oncology. Follicular Lymphoma. https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/follikulaeres-lymphom\/@@guideline\/html\/index.html. Accessed July 2023."},{"issue":"2","key":"245_CR16","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jval.2021.08.013","volume":"25","author":"X Wang","year":"2022","unstructured":"Wang X, Adamson BJ, Briggs A, et al. Approaches for enhanced extrapolation of long-term survival outcomes using electronic health records of patients with cancer. Value Health. 2022;25(2):230\u20137.","journal-title":"Value Health"},{"key":"245_CR17","unstructured":"Haematological Malignancy Research Network. https:\/\/hmrn.org\/. Accessed March 2021."},{"issue":"5","key":"245_CR18","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/ejh.13295","volume":"103","author":"W Knauf","year":"2019","unstructured":"Knauf W, Abenhardt W, Mohm J, et al. Similar effectiveness of R-CHOP-14 and -21 in diffuse large B-cell lymphoma-data from the prospective German Tumour Registry Lymphatic Neoplasms. Eur J Haematol. 2019;103(5):460\u201371.","journal-title":"Eur J Haematol"},{"issue":"suppl 1","key":"245_CR19","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.1182\/blood-2021-147608","volume":"138","author":"ML Palomba","year":"2021","unstructured":"Palomba ML, Ghione P, Patel AR, et al. A comparison of clinical outcomes from updated Zuma-5 (axicabtagene ciloleucel) and the international SCHOLAR-5 external control cohort in relapsed\/refractory follicular lymphoma (R\/R FL). Blood. 2021;138(suppl 1):3543.","journal-title":"Blood"},{"issue":"4","key":"245_CR20","doi-asserted-by":"publisher","first-page":"e289","DOI":"10.1016\/S2352-3026(22)00033-3","volume":"9","author":"C Casulo","year":"2022","unstructured":"Casulo C, Larson MC, Lunde JJ, et al. Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study. Lancet Haematol. 2022;9(4):e289\u2013300.","journal-title":"Lancet Haematol"},{"issue":"suppl 1","key":"245_CR21","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1182\/blood-2021-145870","volume":"138","author":"G Salles","year":"2021","unstructured":"Salles G, Schuster SJ, Fischer L, et al. Retrospective cohort study of treatment outcomes of adult patients with relapsed or refractory low-grade follicular lymphoma (ReCORD-FL). Blood. 2021;138(suppl 1):1349.","journal-title":"Blood"},{"issue":"8","key":"245_CR22","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1200\/JCO.2008.18.1495","volume":"27","author":"JW Friedberg","year":"2009","unstructured":"Friedberg JW, Taylor MD, Cerhan JR, et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol. 2009;27(8):1202\u20138.","journal-title":"J Clin Oncol"},{"key":"245_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9.","journal-title":"BMC Med Res Methodol"},{"key":"245_CR24","unstructured":"Hess K (S original), Gentleman R (R port). Muhaz: hazard function estimation in survival analysis. R package version 1.2.6.1. 2019. https:\/\/rdrr.io\/cran\/muhaz\/. Accessed May 19, 2023."},{"issue":"1","key":"245_CR25","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1137\/1114019","volume":"14","author":"VA Epanechnikov","year":"1969","unstructured":"Epanechnikov VA. Non-parametric estimation of a multivariate probability density. Theory Prob Appl. 1969;14(1):153\u20138.","journal-title":"Theory Prob Appl"},{"issue":"1","key":"245_CR26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2307\/2533197","volume":"50","author":"HG M\u00fcller","year":"1994","unstructured":"M\u00fcller HG, Wang JL. Hazard rate estimation under random censoring with varying kernels and bandwidths. Biometrics. 1994;50(1):61\u201376.","journal-title":"Biometrics"},{"issue":"3","key":"245_CR27","doi-asserted-by":"publisher","first-page":"PA6","DOI":"10.1016\/j.jval.2015.03.034","volume":"18","author":"SJ Snedecor","year":"2015","unstructured":"Snedecor SJ, Howlett C, Mato A. Synthesis of multiple types of survival data within a Weibull proportional hazards meta-analysis: treatment outcomes in patients with double hit lymphomas (DHL). Value Health. 2015;18(3):PA6.","journal-title":"Value Health"},{"issue":"4","key":"245_CR28","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1177\/0272989X16639900","volume":"37","author":"C Jackson","year":"2017","unstructured":"Jackson C, Stevens J, Ren S, et al. Extrapolating survival from randomization trials using external data: a review of methods. Med Decis Making. 2017;37(4):377\u201390.","journal-title":"Med Decis Making"},{"key":"245_CR29","unstructured":"Use of clinical opinion to support extrapolation of survival distributions. www.psiweb.org\/docs\/default-source\/default-document-library\/mario-ouwens-slides.pdf?sfvrsn=2d2adedb_0. Accessed May 19, 2023."},{"key":"245_CR30","unstructured":"National Institute for Health and Care Excellence Decision Support Unit. Technical Support Document 20. https:\/\/www.sheffield.ac.uk\/nice-dsu\/tsds. Accessed June 8, 2022."},{"key":"245_CR31","unstructured":"Therneau TM. A package for survival analysis in S.\u00a0R package version 2.36\u201312. https:\/\/cran.r-project.org\/web\/packages\/survival\/index.html. Accessed June 8, 2022."},{"key":"245_CR32","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v070.i08","volume":"70","author":"CH Jackson","year":"2016","unstructured":"Jackson CH. flexserv: a platform for parametric survival modeling in R. J Stat Softw. 2016;70:i08.","journal-title":"J Stat Softw"},{"issue":"9","key":"245_CR33","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.jval.2021.03.008","volume":"24","author":"I van Oostrum","year":"2021","unstructured":"van Oostrum I, Ouwens M, Remiro-Az\u00f3car A, et al. Comparison of parametric survival extrapolation approaches incorporating general population mortality for adequate health technology assessment of new oncology drugs. Value Health. 2021;24(9):1294\u2013301.","journal-title":"Value Health"},{"issue":"4","key":"245_CR34","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1177\/0272989X16670604","volume":"37","author":"P Guyot","year":"2017","unstructured":"Guyot P, Ades AE, Beasley M, et al. Extrapolation of survival curves from cancer trials using external information. Med Decis Making. 2017;37(4):353\u201366.","journal-title":"Med Decis Making"},{"key":"245_CR35","unstructured":"Plummer M. rjags: Bayesian graphical models using MCMC. R package version 4\u201310. 2019. https:\/\/cran.r-project.org\/web\/packages\/rjags\/rjags.pdf. Accessed May 19, 2023."},{"issue":"suppl 3","key":"245_CR36","doi-asserted-by":"publisher","first-page":"S519","DOI":"10.1016\/j.jval.2019.09.623","volume":"22","author":"H El Alili","year":"2019","unstructured":"El Alili H, Gezin A, Postma M, Ouwens DM, Heeg B. PCN430 Using Bayesian methodologies to inform immature survival extrapolations based on RWD and expert elicitation in non-small cell lung cancer (NSCLC). Value Health. 2019;22(suppl 3):S519.","journal-title":"Value Health"}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-023-00245-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-023-00245-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-023-00245-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T14:22:51Z","timestamp":1700835771000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-023-00245-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,18]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["245"],"URL":"https:\/\/doi.org\/10.1007\/s40487-023-00245-4","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"value":"2366-1070","type":"print"},{"value":"2366-1089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,18]]},"assertion":[{"value":"7 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mahmoud Jaber and Marie-Helene Blanchet Zumofen are employees of and own stock in F. Hoffmann-La Roche Ltd. Javier Sanchez Alvarez was an employee of and owned stock in F. Hoffmann-La Roche Ltd during the development of this manuscript and is currently employed by Evidera Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The original trials used in this analysis obtained patient consent to participate and were performed in accordance with the Helsinki Declaration of 1964. All ethical approvals and permission to access and use non-public data have been granted for this study. All remaining data are publicly available.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}